HAE - Haemonetics Corporation logo

Haemonetics Corporation

HAE

Haemonetics Corporation provides medical technology solutions, including automated plasma collection systems, donor management software, and hemostasis analyzers. Its products serve healthcare providers and plasma centers, enhancing blood management processes.

⚕️ Healthcare NYSE Listed 1991 $ USD
$1,000 invested 30 years ago →$14,122today

Score Overview

1 Year
Score
Net Growth6.78%
Net TrendGrew
Net Income Consistency—
Rev Growth3.63%
Rev TrendGrew
Revenue Consistency—
5 Years
Score7.6
Net Growth139.56%
Net Trend80%
Net Income Consistency—
Rev Growth39.19%
Rev Trend80%
Revenue Consistency—
10 Years
Score
Net Growth495.57%
Net Trend80%
Net Income Consistency
Rev Growth56.01%
Rev Trend80%
Revenue Consistency
20 Years
Score5.3
Net Growth111.59%
Net Trend60%
Net Income Consistency
Rev Growth207.48%
Rev Trend75%
Revenue Consistency
30 Years
Score
Net Growth214.87%
Net Trend57%
Net Income Consistency
Rev Growth346.24%
Rev Trend73%
Revenue Consistency
All Time
Score
Net Growth477.27%
Net Trend60%
Net Income Consistency
Rev Growth7x
Rev Trend77%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Haemonetics Corporation has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • HAE

2002: 74.1% · 2021: 72.5% · free through 2021 · longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-11-17
$ 120.92—
1 Year2025-11-17
$ 74.3262.70%
5 Years2021-11-17
$ 58.07108.23%
10 Years2016-11-17
$ 39.28207.84%
20 Years2006-11-17
$ 22.68433.16%
30 Years1996-11-15
$ 8.5614x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 1.38B$ 103M$ 260M
2026$ 1.33B$ 97M$ 245M
2025$ 1.36B$ 167M$ 306M
2024$ 1.30B$ 117M$ 178M
2023$ 1.16B$ 115M$ 284M
2022$ 993M$ 43M$ 259M
2021$ 870M$ 79M$ 192M
2020$ 988M$ 76M$ 137M
2019$ 967M$ 55M$ 169M
2018$ 903M$ 45M$ 180M
2017$ 886M-$ 26M$ 139M
2016$ 908M-$ 55M$ 115M
2015$ 910M$ 16M$ 160M
2014$ 938M$ 35M$ 192M
2013$ 891M$ 38M$ 179M
2012$ 727M$ 66M$ 228M
2011$ 676M$ 79M$ 196M
2010$ 645M$ 58M$ 141M
2009$ 597M$ 59M$ 156M
2008$ 516M$ 51M$ 133M
2007$ 449M$ 49M$ 229M
2006$ 419M$ 69M$ 250M
2005$ 383M$ 39M$ 185M
2004$ 364M$ 29M$ 118M
2003$ 336M$ 28M$ 49M
2002$ 319M$ 30M$ 67M
2001$ 293M$ 7M$ 74M
2000$ 277M$ 18M$ 61M
1999$ 282M$ 21M$ 56M
1998$ 285M-$ 24M$ 21M
1997$ 309M$ 33M$ 8M
1996$ 278M$ 35M$ 13M
1995$ 262M$ 33M$ 4M
1994$ 248M$ 31M$ 16M
1993$ 216M$ 24M$ 10M
1992$ 176M$ 18M$ 2M
HAE - Haemonetics Corporation logo

Haemonetics Corporation fundamental performance

Between 2021 and 2026, revenue grew from $ 870M to $ 1.33B and net income grew from $ 79M to $ 97M. Revenue increased in 4 of those 5 years; net income in 4.

Between 2016 and 2026, revenue grew from $ 908M to $ 1.33B and net income went from -$ 55M to $ 97M. Revenue increased in 8 of those 10 years; net income in 8.

Haemonetics Corporation currently holds a 20-year HDB Score of 5.3 out of 10. How the HDB Score is calculated.

Membership

Continue HAE’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,188 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$149 / year

or $19/month

Continue with Membership

30-day money-back guarantee.

Explore other companies